NLGN4X

NLGN4X encodes a postsynaptic cell-adhesion molecule that promotes synapse formation and neuronal development, and its disruption is genetically linked to autism-spectrum disorders and X-linked mental retardation, implicating defective synaptogenesis as the predisposing mechanism (PMID:12669065, PMID:14963808). Functional maturation of NLGN4X depends on a single critical amino acid that distinguishes it from the paralog NLGN4Y; this residue governs protein maturation, surface expression, and synaptogenic activity, and ASD-associated mutations clustering around it phenocopy the non-functional NLGN4Y, which cannot compensate for the deficits (PMID:32243781). Synaptic activity is further tuned by phosphorylation at serine 712 by PKA and Cdk5, which bidirectionally controls dendritic spine density and excitatory transmission: phosphorylated S712 reduces mature spines whereas unphosphorylated S712 increases spine density and miniature excitatory postsynaptic current frequency (PMID:40032531). At the circuit and developmental level, loss of NLGN4X delays neurite formation and downregulates postsynaptic genes (PMID:23710042), and knockout reduces the excitation-inhibition ratio in cortical circuits (PMID:24104404). Beyond the nervous system, NLGN4X acts in non-neural contexts—suppressing tumor growth via a VBP1–HIF1A axis in melanoma (PMID:38902533) and presenting an HLA-A*02-restricted tumor-associated antigen recognized by cytotoxic T cells in glioma (PMID:37715782).

1. 2003 Medium

   Established NLGN4X as a synaptic cell-adhesion molecule whose loss-of-function links to autism, framing defective synaptogenesis as a disease mechanism.

   Evidence Genetic sequencing of autism-spectrum siblings identifying mutations in X-linked neuroligin genes

   PMID:12669065

   Open questions at the time

   • No in vitro reconstitution of the synaptogenic mechanism
   • Causality of mutations not functionally demonstrated
2. 2004 Low

   Refined the disease mechanism by showing a truncating mutation removes the transmembrane domain and sequences needed for dimerization and beta-neurexin binding, implying loss of synaptic cell-cell interaction.

   Evidence Sequencing of NLGN4X in a large pedigree with protein domain analysis of a 2-bp deletion

   PMID:14963808

   Open questions at the time

   • Dimerization and neurexin-binding consequences inferred from truncation, not directly tested in vitro
   • Single-lab genetic study
3. 2013 Medium

   Defined a developmental requirement for NLGN4X in neurite formation and postsynaptic gene expression during neuronal differentiation.

   Evidence shRNAmir knockdown in neural stem cells with morphology and whole-genome expression profiling

   PMID:23710042

   Open questions at the time

   • Single-lab loss-of-function model
   • Direct vs. indirect regulation of downstream postsynaptic genes not resolved
4. 2013 Medium

   Connected NLGN4X loss to circuit-level dysfunction by demonstrating reduced excitation-inhibition ratio in cortical networks.

   Evidence Multi-electrode array and patch-clamp electrophysiology of cortical slices from Nlgn4 knockout mice

   PMID:24104404

   Open questions at the time

   • Molecular basis of E/I imbalance not defined
   • Single lab
5. 2020 High

   Identified a single critical residue controlling NLGN4X maturation and synaptogenesis, explaining why the paralog NLGN4Y is non-functional and why ASD mutations near this residue are pathogenic.

   Evidence Biochemistry, electrophysiology, imaging, and site-directed mutagenesis comparing NLGN4X vs NLGN4Y

   PMID:32243781

   Open questions at the time

   • Structural basis of how the residue governs maturation not resolved
   • In vivo consequence of the residue swap not tested
6. 2024 Medium

   Revealed a non-neural tumor-suppressive function of NLGN4X acting through a VBP1–HIF1A axis in melanoma.

   Evidence Loss/gain-of-function, VBP1 knockdown epistasis, transcriptomics, and skin organoid transplantation

   PMID:38902533

   Open questions at the time

   • Mechanism by which NLGN4X controls VBP1 unknown
   • Single lab, non-neural context
7. 2024 Medium

   Showed NLGN4X harbors an HLA-A*02-restricted tumor-associated antigen exploitable for TCR-engineered T cell therapy in glioma.

   Evidence Single-cell TCR sequencing of tetramer-sorted T cells, cytotoxicity assays, and NSG mouse glioma model

   PMID:37715782

   Open questions at the time

   • Endogenous antigen processing/presentation in vivo not fully characterized
   • Single lab
8. 2025 High

   Established phosphorylation of NLGN4X at serine 712 by PKA and Cdk5 as a bidirectional switch controlling spine density and excitatory transmission.

   Evidence Site-directed mutagenesis of S712, kinase activity assays, spine morphology analysis, and mEPSC electrophysiology

   PMID:40032531

   Open questions at the time

   • Upstream signals triggering PKA/Cdk5 phosphorylation unknown
   • Single lab

• How NLGN4X's synaptic adhesion function is mechanistically connected to its non-neural roles (VBP1–HIF1A regulation, antigen presentation) remains unresolved.
• No unifying biochemical mechanism linking synaptic and tumor-context functions
• Neurexin-binding consequences of disease mutations not directly demonstrated in the corpus